bioAffinity Technologies, Inc. (BIAF): Nasdaq/NYSE listing notice — bioAffinity receives Nasdaq delisting notice; July CyPath Lung sales up 72% over prior monthly average

bioAffinity Technologies, Inc.

Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.
Stockholders' equity of $1,439,404 at March 31, 2025 remains below the $2.5M minimum, adding a second delisting basis.
Company intends to appeal by Aug 14, 2025; delisting scheduled for Aug 18 if appeal not filed.
July completed tests for CyPath Lung surged 72% over the average of the first six months of 2025.
Company reaffirms forecast of 3X year-over-year revenue for CyPath Lung; back-to-back record months in June and July.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-023488

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.